SCHEMBL7032769

SCHEMBL7032769

CC(=O)c1oc2ccc(C)cc2c1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.61
NPC1 O15118 10/20 0.60
RAB9A P51151 9/20 0.56
SMN1; SMN2 Q16637 3/20 0.53
PKM P14618 1/20 0.53
GAA P10253 1/20 0.53
MCL1 Q07820 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPT P10636 3/20 0.52
KDM4E B2RXH2 3/20 0.52
HSD17B10 Q99714 3/20 0.52
TP53 P04637 2/20 0.52
HPGD P15428 2/20 0.52
TSHR P16473 2/20 0.52
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065472 0.86 MCL1 (0.71) KCNH2NPC1RAB9ASMN1; SMN2PKM
SCHEMBL19661814 0.84 KCNH2 (0.60) KCNH2NPC1RAB9ASMN1; SMN2PKM
SCHEMBL29539987 0.84 KCNH2 (0.60) KCNH2NPC1RAB9ASMN1; SMN2PKM
SCHEMBL11545219 0.83 RAB9A (0.58) NPC1RAB9ASMN1; SMN2GAAMCL1
SCHEMBL11686876 0.83 MCL1 (0.77) KCNH2RAB9ASMN1; SMN2PKMMCL1
SCHEMBL11095152 0.81 PKM (0.64) KCNH2NPC1RAB9ASMN1; SMN2PKM
SCHEMBL6238414 0.80 KCNH2 (0.63) KCNH2NPC1RAB9ASMN1; SMN2PKM
SCHEMBL30608265 0.79 NPC1 (0.61) KCNH2NPC1RAB9ASMN1; SMN2GAA
SCHEMBL19661983 0.79 KCNH2 (0.66) KCNH2NPC1RAB9AMAPTKDM4E
SCHEMBL114250 0.78 KMT2A (0.60) KCNH2NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926332-B2 Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them EGIS GYOGYSZERGYAR ZRT. (HU) 2018-03-27 US disclosed
US-20170002020-A1 NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM EGIS GYOGYSZERGYAR ZRT. (HU) 2017-01-05 US disclosed
EP-0826764-B1 Perfuming compositions comprising substituted 2-acetylbenzofuranes HAARMANN & REIMER GMBH (DE) 2003-02-26 EP disclosed
US-5972878-A A PERFUME OIL FOR PERFUMING COSMETIC COMPOSITIONS, CLEANING COMPOSITIONS, DETERGENT COMPOSITIONS, SOFTENER COMPOSITIONS, DISINFECTANT COMPOSITIONS, TEXTILE TREATMENT COMPOSITIONS AND PERFUME COMPOSITIONS HAARMANN & REIMER GMBH (DE) 1999-10-26 US disclosed
EP-0826764-A2 Use of substituted 2-acetylbenzofuranes as perfuming agents HAARMANN & REIMER GMBH (DE) 1998-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002020-A1 NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM GABRB2, GABRB3, GABRA5 KCNH2 564/4885NPC1 2358/4885RAB9A 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.